- AU$47.27m
- AU$42.83m
- AU$32.33m
Australia's Cyclopharm gains most in 8-months on Technegas rollout deal
Australia's Cyclopharm rises on HY revenue forecast
Brief: Cyclopharm Forecasts 1H Global Revenue Of A$17.1 Million
Brief: Cyclopharm Says David Heaney To Retire As Non-Executive Chair
Brief: Cyclopharm Secures Multi-Site Agreement With Northwestern Medicine
Australia's Cyclopharm rises on agreement with Northwestern Medicine
Australia's Cyclopharm rises on deal with University of Pennsylvania Health System
Brief: Cyclopharm Posts FY Prelim Net Loss Attributable A$17.2 Million
Brief: Cyclopharm To Raise A$14 Million (Before Costs) At A$0.95 Per Share
Australia's Cyclopharm drops to one-week low on discounted placement
Brief: Cyclopharm Logs FY Unaudited Operating Revenue A$32.3 Mln
Brief: Cyclopharm Seeks Trading Halt
Brief: Cyclopharm Confirms Insurer Accepted Indemnity In Respect Of Proceedings
Australia's Cyclopharm rises on med-tech clinical guideline win in US
Brief: Cyclopharm Says Served With Legal Proceedings By 4D Medical
Brief: Cyclopharm Secures Maximum U.S. Patent Extension For Technegas To 2031
Brief: Cyclopharm Announces Receipt Of Installation Purchase Order For Technegas
Australia's Cyclopharm rises on additional purchase orders from US
Brief: CYC Signs 5-Year Agreement With USA Veterans Administration